Register Login

ARVINAS, INC. (ARVN)

(10% Negative) ARVINAS, INC. (ARVN) Announces Delay in option Trials for ER+/HER2- Due to Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 1, 2026, 4:58 p.m.

    📋 ARVINAS, INC. (ARVN) - Clinical Trial Update

    Filing Date: 2026-05-01

    Accepted: 2026-05-01 12:58:05

    Event Type: Clinical Trial Update

    Event Details:

    ARVINAS, INC. (ARVN) Announces Clinical Trial Update ARVINAS, INC. (ARVN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: option, received
    • Diseases/Conditions: ER+/HER2-, estrogen
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process, Regulatory Timeline
    • Collaboration: VEPPANU
      • TArgeting Chimera (PROTAC), estrogen receptor degrader approved in the U.S. for use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2– negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA- authorized test, with disease progression following at least one line of endocrine therapy. 5 In July 2021
      • TArgeting Chimera (PROTAC), a type of heterobifunctional protein degrader therapy. “Today’s FDA approval is a transformative moment for Arvinas as we achieve our first approved medicine and the first-ever approved PROTAC therapy based on the technology we’ve pioneered since 2013
      • targeting a key biological driver of resistance to current therapies. “The approval of VEPPANU is an important milestone for patients, their caregivers, and physicians,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. “VEPPANU addresses an unmet need for patients with this aggressive form of breast cancer who have progressed on their initial therapy. Today’s approval provides a new oral treatment option that showed improved progression free survival when compared to the current standard of care, fulvestrant, which is administered via an intramuscular injection.” VEPPANU was discovered by Arvinas and jointly developed by Arvinas and Pfizer. FDA approval was granted based on data from VERITAC-2 (NCT0565

    🔬 Clinical Development Pipeline (ARVINAS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Vepdegestrant DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    ARV-471 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    single dose of vepdegestrant as tablet formulation (Treatment C) DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    ARV-806 DRUG Phase PHASE1 KRAS G12D Mutation ClinicalTrials.gov
    ARV-393 DRUG Phase PHASE1 Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) ClinicalTrials.gov
    Abiraterone Other Phase PHASE1 Prostate Cancer Metastatic ClinicalTrials.gov
    Bavdegalutamide Other Phase PHASE1 Prostate Cancer Metastatic ClinicalTrials.gov
    Dabigatran etexilate DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Fulvestrant DRUG Phase PHASE3 Advanced Breast Cancer ClinicalTrials.gov
    [oxoisoindolin-14C]ARV-471 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    [phenyl-14C]ARV-471 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Carbamazepine DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    esomeprazole DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Rosuvastatin DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Itraconazole DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    single dose of vepdegestrant as tablet formulation (Treatment B) DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    single dose of vepdegestrant as tablet formulation (Treatment A) DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Midazolam DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Vepdegestrant (Test) DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Vepdegestrant (Reference) DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    ARV-110 in Combination with Abiraterone DRUG Phase PHASE1 Prostate Cancer Metastatic ClinicalTrials.gov
    ARV-471 in combination with Everolimus DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Samuraciclib DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Letrozole DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Vepdegestrant (ARV-471/PF-07850327) DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Abemaciclib DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    ARV-471 in combination with palbociclib (IBRANCE®) DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    PF-07220060 DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Ribociclib DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Glofitamab DRUG Phase PHASE1 Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) ClinicalTrials.gov
    Surgical resection of breast tumor PROCEDURE Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Anastrozole DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    ARV-110 DRUG Phase PHASE1 Prostate Cancer Metastatic ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ARVINAS, INC.
    • Ticker Symbol: ARVN

Search

News categories